Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Ryo Ashida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8388-0135; OpenAlex author ID A5024662056. Sources: OpenAlex.

Their work

Papers
57 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
73
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 6 papers · 2021: 9 papers · 2022: 7 papers · 2023: 10 papers · 2024: 3 papers · 2025: 5 papers · 2026: 10 papers

Papers 50 of 57

  1. Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria. Co-author DOI 10.1007/s00595-025-03223-7↗
  2. Intraoperative decision-making for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis: Proposal of a pathology-based weighted risk … Co-author DOI 10.1016/j.suronc.2026.102559↗
  3. Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Co-author DOI 10.1097/sla.0000000000007152↗
  4. Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. Co-author DOI 10.1245/s10434-025-18556-3↗
  5. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  6. ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. Co-author DOI 10.1245/s10434-026-19112-3↗
  7. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  8. Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19244-6↗
  9. ASO Author Reflections: Rethinking Resectability in Left-Sided Pancreatic Cancer-The Clinical Meaning of Radiological Adjacent Organ Invasion. Co-author DOI 10.1245/s10434-026-19394-7↗
  10. ASO Visual Abstract: Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19416-4↗
  11. Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer. First author DOI 10.1002/ags3.70052↗
  12. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Co-author DOI 10.1007/s00066-025-02433-9↗
  13. Clinical significance of resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis. Co-author DOI 10.1016/j.surg.2024.10.016↗
  14. Impact of Perioperative Hemoglobin A1c Levels on Survival Outcomes of Patients With Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1097/as9.0000000000000597↗
  15. Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. First author DOI 10.1097/mpa.0000000000002485↗
  16. Predictive factors of actual 5-y recurrence-free survival after upfront surgery for resectable pancreatic cancer: Exploration of patients who did not require n… Co-author DOI 10.1002/ags3.12834↗
  17. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. First author DOI 10.1093/bjs/znae059↗
  18. Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report. Co-author DOI 10.1186/s13053-024-00283-7↗
  19. Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. First author DOI 10.1002/ags3.12636↗
  20. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. Co-author DOI 10.1007/s00423-023-02906-4↗
  21. Corrigendum to Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer: [Surgery. 2022;172(6):1776-81, DOI: 10… Co-author DOI 10.1016/j.surg.2023.05.001↗
  22. Characterization of pancreatic cancer with ultra-low tumor mutational burden. First author DOI 10.1038/s41598-023-31579-8↗
  23. Assessing target localization accuracy across different soft-tissue matching protocols using end-exhalation breath-hold cone-beam computed tomography in patien… Co-author DOI 10.1093/jrr/rrad048↗
  24. Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced … Co-author DOI 10.1186/s13014-023-02288-3↗
  25. Correction: Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for local… Co-author DOI 10.1186/s13014-023-02321-5↗
  26. Prognostic analysis of curatively resected pancreatic cancer using harmonized positron emission tomography radiomic features. First author DOI 10.1186/s41824-023-00163-8↗
  27. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13564-7↗
  28. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Us… Co-author DOI 10.1245/s10434-023-13629-7↗
  29. The prognostic impact of ABO blood type in pancreatic cancer: Relevance to adjuvant chemotherapy. Co-author DOI 10.1002/jhbp.1152↗
  30. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Co-author DOI 10.1016/j.pan.2022.03.017↗
  31. Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1016/j.surg.2022.09.025↗
  32. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Co-author DOI 10.1245/s10434-022-11624-y↗
  33. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Co-author DOI 10.1245/s10434-022-11628-8↗
  34. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologic… Co-author DOI 10.1245/s10434-022-11639-5↗
  35. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Co-author DOI 10.1245/s10434-022-11662-6↗
  36. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. Co-author DOI 10.1007/s00535-020-01730-7↗
  37. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13304-020-00792-9↗
  38. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2021.08.009↗
  39. Statistical shape model-based planning organ-at-risk volume: application to pancreatic cancer patients. Co-author DOI 10.1088/1361-6560/abcd1b↗
  40. Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001848↗
  41. Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09066-5↗
  42. Clinical Implication of Node-negative Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09543-x↗
  43. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-09593-9↗
  44. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-021-09660-1↗
  45. Impact of interfractional anatomical variation and setup correction methods on interfractional dose variation in IMPT and VMAT plans for pancreatic cancer pati… Co-author DOI 10.1002/acm2.12883↗
  46. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Co-author DOI 10.1007/s00423-020-01874-3↗
  47. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  48. Positional repeatability and variation in internal and external markers during volumetric-modulated arc therapy under end-exhalation breath-hold conditions for… Co-author DOI 10.1093/jrr/rraa054↗
  49. Middle segment-preserving pancreatectomy for multifocal pancreatic ductal adenocarcinoma located in the head and tail of the pancreas: a case report. Co-author DOI 10.1093/jscr/rjaa383↗
  50. Multiple Carcinomas and Intraepithelial Neoplasms in a Case of Familial Pancreatic Cancer: Rapid Morphological Changes in the Pancreatic Cyst and Pathological … Co-author DOI 10.2169/internalmedicine.3882-19↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuhiko Uesaka · 45 shared papers, 2017–2026 · strength 7.93
  2. Teiichi Sugiura · 42 shared papers, 2017–2026 · strength 7.38
  3. Katsuhisa Ohgi · 39 shared papers, 2019–2026 · strength 7.15
  4. Yukiyasu Okamura · 25 shared papers, 2017–2026 · strength 3.70
  5. Mihoko Yamada · 18 shared papers, 2018–2026 · strength 3.37
  6. Yoshiyasu Kato · 10 shared papers, 2025–2026 · strength 2.74
  7. Takaaki Ito · 15 shared papers, 2017–2022 · strength 1.74
  8. Takashi Mizowaki · 9 shared papers, 2018–2025 · strength 1.45
  9. Taisuke Imamura · 10 shared papers, 2019–2024 · strength 1.40
  10. Michio Yoshimura · 8 shared papers, 2019–2025 · strength 1.38
  11. Mitsuhiro Nakamura · 7 shared papers, 2019–2023 · strength 1.16
  12. Akiko Todaka · 8 shared papers, 2019–2024 · strength 1.15
  13. Takumi Kitahama · 4 shared papers, 2026 · strength 1.14
  14. Kenichi Urakami · 5 shared papers, 2023–2026 · strength 1.01
  15. Keiichi Ohshima · 5 shared papers, 2023–2026 · strength 1.00
  16. Hidemasa Kubo · 5 shared papers, 2022–2025 · strength 0.87
  17. Mitsuro Kanda · 3 shared papers, 2026 · strength 0.84
  18. Masamichi Hayashi · 3 shared papers, 2026 · strength 0.84
  19. Keizo Fujita · 3 shared papers, 2026 · strength 0.84
  20. Kentaro Yamazaki · 4 shared papers, 2022–2025 · strength 0.83
  21. Yuya Miura · 4 shared papers, 2022–2026 · strength 0.79
  22. Ayaka Ogawa · 3 shared papers, 2023–2025 · strength 0.62
  23. Takahiro Iwai · 3 shared papers, 2023–2025 · strength 0.62
  24. Tomoko Norose · 3 shared papers, 2022–2026 · strength 0.59
  25. Jun Shibamoto · 2 shared papers, 2025–2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.